Genetix Biotherapeutics Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
Previously recorded as Bluebird Bio, Inc. (to 2025)
0
Ending by 2030
Sep 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 23, 2026The maintenance fee for Gene Therapy Vectors for Adrenoleukodystrophy and Adrenomyeloneuropathy (US 9,061,031) comes due Dec 23, 2026. Unpaid by Jun 23, 2027, it lapses early.
- 2 fees due Jun 5 to 10, 2027 · next Jun 5
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,280,435 | Gene Therapy Methods In force · High confidence | In force | High confidence | |
| US 9,783,822 | Gene Therapy Methods In force · High confidence | In force | High confidence | |
| US 8,858,928 | Gene Therapy Vectors for Adrenoleukodystrophy and Adrenomyeloneuropathy In force · High confidence | In force | High confidence | |
| US 9,061,031 | Gene Therapy Vectors for Adrenoleukodystrophy and Adrenomyeloneuropathy In force · Medium confidence | In force | Medium confidence | |
| US 9,789,139 | Gene Therapy Vectors for Adrenoleukodystrophy and Adrenomyeloneuropathy In force · Medium confidence | In force | Medium confidence | |
| US 9,988,644 | Compounds for Improved Viral Transduction In force · High confidence | In force | High confidence | |
| US 10,501,759 | Compounds for Improved Viral Transduction In force · Medium confidence | In force | Medium confidence | |
| US 10,907,177 | Compounds for Improved Viral Transduction In force · Medium confidence | In force | Medium confidence | |
| US 11,834,668 | Compounds for Improved Viral Transduction In force · Medium confidence | In force | Medium confidence | |
| US 12,234,476 | VCN Enhancer Compositions and Methods of Using the Same In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.